We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 18, 2020

Osimertinib vs First-Generation EGFR-TKIs in EGFR-Mutant Advanced NSCLC Without Baseline CNS Metastasis

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Survival Outcomes and Symptomatic Central Nervous System (CNS) Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer Without Baseline CNS Metastasis: Osimertinib vs. First-Generation EGFR Tyrosine Kinase Inhibitors
Lung Cancer 2020 Nov 05;[EPub Ahead of Print], Y Zhou, B Wang, J Qu, et al

Further Reading